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Abstract
Biomarker subpopulations have become increasingly important for drug
development in targeted therapies. The use of biomarkers has the po-
tential to facilitate more effective outcomes by guiding patient selection
appropriately, thus enhancing the benefit-risk profile and improving trial
power. Studying a broad population simultaneously with a more targeted
one allows the trial to determine the population for which a treatment
is effective and allows a goal of making approved regulatory labeling as
inclusive as is appropriate. We examine new methods accounting for the
complete correlation structure in group sequential designs with hypothe-
ses in nested subgroups. The designs provide full control of family-wise
Type I error rate. This extension of previous methods accounting for ei-
ther group sequential design or correlation between subgroups improves
efficiency (power or sample size) over a typical Bonferroni approach for
testing nested populations.
1 Introduction
Conventional design with only one primary study population (an overall popula-
tion) has recently been challenged [4, 14], particularly when the treatment effect
may be heterogeneous due to observable clinical or biologic/genomic character-
istics. For example, in recent oncology clinical trials, biomarker subpopulations
(biomarker +/-) have become increasingly important for drug development in
tailored therapies to fulfill regulatory commitments [25]. The use of biomarkers
has the potential to facilitate the availability of safer and more effective drug or
biotechnology products, to guide dose selection, and to enhance their benefit-
risk profile [5]. While the overall population targets the goal of making the
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approved regulatory labeling as inclusive as possible, evaluating the benefit in a
biomarker positive subpopulation can mitigate the risk that biomarker negative
patients could dilute the efficacy in the overall population.
In the situation of testing hypotheses in multiple populations, multiplicity
needs to be carefully considered to ensure strong control of the family-wise Type
I error (or family-wise error rate, FWER) and to maximize the study power. In
the setting described above, there is a known correlation structure in the asymp-
totic distribution for the joint test statistics across interim and final analysis as
well as across populations. To-date, people have designed trials accounting for
correlation in interim timing [11] or subpopulations [23, 8], respectively, but have
not taken advantage of the full correlation structure including both populations
and interim analyses, leading to stricter bounds than necessary to control Type
I error. Therefore, in this paper, we extend the group sequential design setup
with multiple biomarker populations and develop the method and calculations
with less conservative bounds, which results in a smaller required sample size
or greater power, while controlling the FWER. This is a realization of the im-
proved weighted parametric test mentioned in [16] for multiple testing in group
sequential trials using graphical approaches.
In section 2, we briefly review methods in group sequential design. We
introduce the complete correlation structure (CCS) incorporating both interim
analyses and populations in Section 3. In the same section, the calculations for
adjusted nominal alpha levels, power for hypothesis testing in each population
and sample size are also presented. The effect of CCS on clinical trial design
is demonstrated in Section 4, and an application of CCS is shown in Section
5. Discussion and extensions of CCS appear in Section 6. Example R program
code is included in Appendix C and Appendix D.
2 Background
Group sequential design has played an increasingly important role in modern
clinical trials for ethical reasons and economic considerations. In group se-
quential design, interim analyses are performed during the trial. Further study
follow-up may be stopped in accordance with a pre-defined stopping rule as soon
as conclusive results are observed. Therefore, a conclusion may be reached at
an earlier stage with lower financial and human cost. More importantly group
sequential design offers the possibility to accelerate replacement of an inferior
therapy by a superior one compared to fixed sample size study design where a
decision only can be made at the end of the trial. One aspect of group sequen-
tial design is to control temporal correlation among interim analyses and the
final analysis. Pocock [19, 20] and OBrien and Fleming [18] initially popularized
group sequential test procedures to manage multiplicity.
Lan and DeMets [13] introduced non-decreasing alpha-spending functions to
determine interim efficacy bounds. Their method loosened the rules required by
the Pocock and O’Brien and Fleming approaches, allowing flexibility in timing
of analysis. They developed spending functions to approximate the Pocock
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and OBrien and Fleming designs. Kim and DeMets [12] as well as Hwang,
Shih and DeCani [9] also proposed flexible one-parameter families that again
can approximate Pocock or OBrien and Fleming as well as other boundaries. A
comprehensive illustration of group sequential design can be found, for example,
in Jennison and Turnbull [11], Proschan, Lan, and Wittes [21], or Wassmer
and Brannath [27]. Anderson and Clark [2] suggested 2-parameter spending
functions that could be used to further customize bounds in a fit-for-purpose
manner.
Above we introduced methods that were applied to a single endpoint and
population for a single hypothesis. However, it is common to have multiple
hypotheses regarding different endpoints and populations with group sequential
analysis, increasing the complexity of Type I error control. Here we consider
the case of testing the treatment effect in nested populations within a single
clinical trial. Maurer and Bretz [16] showed the usage of a graphical approach
in group sequential design when multiple hypotheses were tested in a trial. Later
in Maurer, Glimm, and Bretzs work [17], they extended the algorithm of the
test procedure by implementing group sequential boundaries and suggested its
application to a comparison of multiple endpoints for a subgroup and an overall
population. However, they did not provide detailed instruction on results for
population correlations.
Another useful application of group sequential method is to account for corre-
lation among subgroups (sub-populations) and the overall population. Spiessens
and Debois [23] suggested the correlation of test statistics between nested sub-
group and the overall population can be addressed using the same method in
interim analysis (i.e. group sequential design) because it could improve the ef-
ficiency of clinical trials while controlling the FWER. Holmgren [8] proposed
a similar concept using group sequential design boundaries at early phase (e.g.
phase II) in the decision of choosing a biomarker expression level used in later
phase (phase III) trials. However, none of these papers accounts for the benefit
gained when simultaneously accounting for temporal and population correlation,
a situation that arises increasingly in oncology clinical trials.
In this paper, we synthesize the concepts regarding population correlation
from[23, 8] and incorporate it with [16] on multiplicity control for multiple hy-
potheses in group sequential design. We propose a complete correlation struc-
ture (CCS) for the covariance matrix of test statistics that accounts for both
temporal and population correlations in group sequential design to improve de-
sign efficiency.
3 Methods
3.1 Complete Correlation Structure
Jennison and Turnbull [11] summarize the asymptotic distribution of test statis-
tics in group sequential design. We extend this to the above circumstance by
the proposed CCS method accounting for correlations among test statistics at
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multiple analyses over time (temporal perspective) as well as of multiple pop-
ulations. We consider a 2-arm clinical trial comparing the treatment effect of
an experimental treatment group to a control group in I nested biomarker sub-
groups, including the overall population. Each population has an hypothesis,
and these hypotheses are evaluated at K analyses. We let i denote the index for
increasing nested populations, i = 1, . . . , I, while k represents the index for the
stage of interim analyses and final analysis, k = 1, . . . ,K. Let nik be the num-
ber of observations (or number of events for time-to-event endpoints) collected
cumulatively through stage k in population i.
Let θi represent the underlying effect for experimental vs. control treat-
ment in population i for i = 1, 2, . . . , I. We assume Hi0: θi = 0 represents
no treatment effect for the experimental treatment relative to control in pop-
ulation i, while Hia: θi = θia > 0 represents an advantage for experimental
treatment. Let Zik be the standardized test statistic for nested population i at
stage k = 1, . . . ,K, i = 1, , I. We let nik represent the sample size for a bino-
mial or normal endpoint or the number of events for a treatment comparison in
population i at analysis k. For each population, we assume E(Zik) = θi
√
nik,
V ar(Zik) = 1; this is the so-called canonical form of [11]. We will demon-
strate that for cases where group sequential theory can be applied either across
k = 1, . . . ,K or populations i = 1, . . . , I that we further have a K × I-variate
normal distribution with
E(Zik) =
√
nikθi
Var(Zik) = 1
(1)
with a known covariance structure for each pair (Zik, Zi′k′) for 1 ≤ i, i′ ≤ I,
1 ≤ k, k′ ≤ K given by
Cov(Zik, Zi′k′) =
ni∧i′k∧k′√
nikni′k′
(2)
where the operator ∧ represents the minimum. In the numerator for this co-
variance for a time-to-event outcome, we have the number of events included
in both (intersection) test statistics for which we are computing the covariance.
The denominator has the geometric mean of the events considered in each test
statistic separately. For a normal or binary outcome, we would count observa-
tions rather than events. For k = k′, this is the result from [23, 8]. For i = i′,
this is a standard group sequential design result. Combining these two results
(e.g., independent increment in population and then an increment or decrement
in time) yields the general result above. With the entire correlation structure,
we can calculate adjusted nominal alpha levels, population power, and sample
size that produce a more efficient design than one that does not account for the
entire correlation structure. A detailed derivation is provided in Appendix A.
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3.2 Weighted Parametric Testing Bounds
When working with sets of hypotheses, we will let I represent the set of popu-
lation indices rather than the number of populations I as in Section 3.1. For a
set of indices J ⊆ I, we denote the intersection null hypothesis as
HJ = ∩i∈JHi0. (3)
The closed testing principle [15] means we can reject an individual null hypoth-
esis Hi0 for population i ∈ I if for all J ⊆ I with i ∈ J we can reject HJ .
We define a test of HJ using a set of bounds bik, i ∈ J, 1 ≤ k ≤ K. With
these bounds, we reject HJ if for any i ∈ J, 1 ≤ k ≤ K we have Zik ≥ bik.
As noted by [16], the usual sequentially rejective approach has not been proven
acceptable for use here since we have not demonstrated consonance. To reject an
individual null hypothesis Hi0 we must reject HJ at level α for every J ⊆ I with
i ∈ J. The complete correlation structure and multivariate normal distribution
to can be used to compute the probability to reject HJ under arbitrary values
of θi for i ∈ J :
1− Pr (∩i∈J,1≤k≤K{Zik < bik}|θi, i ∈ J) . (4)
We have used the mvtnorm R package [6] for this computation.
3.2.1 Computing Testing Bounds
To set the above bounds to control Type I error for testing under the intersection
hypothesis HJ at level α, we follow the allocation and reallocation approach of
[3]. Thus, we set a weights wi(I), for i ∈ I and a transition matrix G =
(gij), i, j ∈ I. For subset J ⊆ I, these weights can be translated into weights
wi(J) for i ∈ J to test HJ . The information fraction at stage k for population
i is tik = nik/niK . While we generally assume tik = tk across populations,
this is not necessary. We define a spending function family as in [16] for each
population as fi(t; γ) for 0 < γ < 1 and t ≥ 0. We further require fi(0; γ) = 0,
fi(t; γ) = 1 for t ≥ 1, fi(t; γ) increasing in both t and γ and the other conditions
on spending function families of [16].
We present 3 algorthims for deriving testing bounds for HJ , J ⊆ I. This
involves both deriving bounds at the time of design using planned informa-
tion (sample size or event counts at each analysis), as well as updating bounds
if observed information at an analysis (interim or final) differs from planned.
The first algorithm is presented here and the other two in Appendix B. The 3
approaches can be described briefly as follows:
Algorithm 1 Adjust current and future bounds at time of each analysis.
Algorithm 2 Adjust current bounds at time of each analysis.
Algorithm 3 Allocate excess α to largest population only.
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Algorithm 1
For a given J ⊆ I and sequentially for analysis k ∈ 1, . . . ,K:
1. Assume for j < k that bounds bij = cij(J), j < k, i ∈ J have already been
set. These will remain unchanged once finalized at analysis k.
2. Based on updated nik and future planned nij , k < j ≤ K, i ∈ J bounds
for analyses j = k, . . .K are re-planned.
a. Choose a nominal α∗k(J) ≥ α.
b. Set bij for k ≤ j ≤ K to control Type I error for hypothesis Hi0 at
level fi(tij ;α
∗
k(J)× wi(J)) at analysis j; i.e.,
1− Pr({Zij < bij} ∩1≤j′<j {Zij′ < cij′(J)}|Hi0)
= fi(tij ;wi(J)× α∗k(J)).
(5)
This can be done with available group sequential design software such
as in the gsDesign R package [1].
c. Update α∗k(J) until the above bounds control the overall testing level
for HJ at level α; i.e.,
1−Pr(
⋂
i∈J
{∩1≤j<k{Zij < cij(J)} ∩k≤j≤K {Zij < bij}} |HJ) = α. (6)
This can be done as noted in equation (4).
d. After the appropriate α∗k(J) has been derived, we set cik(J) = bik.
4 Evaluating design properties
4.1 Population Power and Sample Size
When a study is designed, the CCS can be calculated by prevalence of biomarker
populations and the design interim analysis timing. Here we assume the infor-
mation accumulates at the same rate for different populations under the null
and alternative hypothesis to simplify. For example, consider a study with 2
populations (biomarker subgroup and overall population) and 3 analyses (two
interim analyses and one final analysis). Assume further that the prevalence
of the biomarker subgroup is p, and the design interim analysis timing based
on information fraction is t1 and t2 at interims 1 and 2, respectively. The co-
variance matrix for test statistics (Z11, Z21, Z12, Z22, Z13, Z23) is as same as in
Section 3.3 and can be calculated as
1
√
p
√
t1/t2
√
pt1/t2
√
t1
√
pt1
1
√
pt1/t2
√
t1/t2
√
pt1
√
t1
1
√
p
√
t2
√
pt2
1
√
pt2
√
t2
1
√
p
1
 (7)
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With the CCS, we find cij(J) as in Algorithm 1 above, providing more
generous bounds than a Bonferroni-adjustment approach. This leads to either
a smaller sample size requirement or greater power as demonstrated below in
Section 5.
4.2 Effect of Biomarker Prevalence
Next, we demonstrate the impact of incorporating CCS in a simple case with
only one interim analysis (i.e., K = 2) and one subpopulation (i.e., I = 2)
planned; example R code is provided in Appendix C. Assuming the FWER is
equally split to the subgroup and the overall population (i.e. w1 = 0.5, w2 =
0.5). We use the Lan and DeMets spending function approximating OBrien and
Fleming bounds. We also assume the interim analysis information fraction (ti1;
proportion of final planned events) at 0.5 and adjust subgroup proportion from
0.3 to 0.8 to investigate effect caused by the prevalence of the biomarker sub-
group. Define, pik = nik/nIk, which is the same for k = 1, 2, if the information
accumulates at the same rate for the two populations. Additionally, the effect
size for subgroup is set at 0.15. In order to maintain the same power for both
populations, we set the effect size for overall population with a proportion of√
p the effect size in subgroup (i.e. effect size 0.106 for overall population when
the prevalence of biomarker subgroup is p = 0.5).
Figures 1-3 showed the effect of biomarker prevalence (p1k) to adjusted nom-
inal α-level (wi(I)α
∗
K(I)), population power, and sample size.
5 Example in an Oncology Clinical Trial
In this section, we show the implementation of CCS in a hypothetical oncology
clinical trial. Assume a 2-arm trial with a primary endpoint of overall survival
(OS). Under the complete null hypothesis the distribution of time-to-death is
7
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Table 1: Comparison of Bonferroni-adjusted vs. CCS-Adjusted Design.
Value Bonferroni CCS
Subgroup Overall Subgroup Overall
Nominal α level 1.25% 1.25% 1.53% 1.53%
Population power1 90% 90% 91.44% 91.36%
Number of events2 296 434 283 415
IA1 IA2 FA IA1 IA2 FAl
Z statistic bound 3.35 2.67 2.28 3.24 2.58 2.21
Hazard ratio bound 0.62 0.73 0.79 0.63 0.74 0.80
1 With fixed HR(0.65/0.70) and sample size (296/434) in subgroup/overall population.
2 With fixed HR (0.65/0.70) and power (90%) in subgroup/overall population.
assumed to follow an exponential distribution with a median of 17.5 months
in both the treatment groups and populations. The drop-out rate is assumed
to be 3% annually. The FWER of 2.5% (1-sided) is equally distributed to the
subgroup and all subjects. For the alternate hypothesis, we assume the hazard
ratio (HR) for OS is 0.65 in the subgroup and HR=0.7 in the overall population.
We expect 434 OS events overall with 296 in subjects with biomarker (+) with
90% power in both populations. The first interim analysis (IA1) is planned at
50% of final planned events, the second interim analysis (IA2) is planned at
75% of final planned, and the final analysis (FA) is conducted when all targeted
event counts have been achieved. The prevalence of biomarker (+) subgroup is
assumed to be 60%. For detailed R program code, please see Appendix D.
As part of the above, we used the CCS and Algorithm 1 to find cij(J). We
used equation (4) to compute the power for these bounds and adjust the sample
size to achieve 90% power for each population at the adjusted nominal α-level
generated using Algorithm 1 under the complete null hypothesis.
Table 1 below shows the comparison of Bonferroni-adjusted group sequen-
tial design (adjusted with temporal correlations only) and CCS group sequential
design (adjusted with both temporal and population correlations) in several el-
ements. The nominal testing level of 1.53% vs. 1.25% using Bonferroni may
seem small; however, we note that the sum of the 2 nominal alpha levels for
group sequential testing is 1.277% (vs 1.25% which is Bonferroni approach for
interim analysis and final analysis without considering temporal correlation)
when testing half-way through the trial with overall alpha=1.25% and OBrien-
Fleming-like spending. Thus, the gains from incorporating population correla-
tions here are greater than those correlations over time. This is largely due to
the substantial spend on each population whereas there is little spending for
this example at interim analysis.
The nominal alpha level increases from 1.25% to 1.53% when the CCS is
adjusted in the group sequential design and FWER is controlled at the same
level of 2.5%. The impact of the adjusted nominal alpha level is reflected in Z
statistic bounds as well. For example, the bound at IA1 decreases from 3.35
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to 3.24 after adjusting for the CCS. In Table 1, we present the comparison of
hazard ratio bounds showing CCS in group sequential design has a minor release
and flexible restriction in hypothesis testing. In addition, the gain from CCS
group sequential design includes a smaller required number of events with a
4.4%-saving in each population. Lastly, population power increases from 90%
to 91.4% with fixed hazard ratio and sample size in both subgroup and overall
populations.
The cost of a clinical trial is always an essential concern, and one way to
control the budget is recruiting minimum but sufficient patients in the trial.
The example above shows a 19-event saving in the overall population after
applying CCS in group sequential design. When calculating the number of
patients required in this example, a 33-patient (721-688) savings is realized. A
recent report in Journal of Clinical Oncology [24] showed the cost of a phase
IIIA oncology trial ranged from $75,000 to $125,000 per patient. Assuming
the cost per patient in a trial is $100,000, we would save $3.3 million with the
application of CCS group sequential design in this example. Alternatively, a
1.36% power increase in Table 1 applied to a trial that could result in a drug
approval worth $100 million would have a value of $1.36 million.
6 Extensions
6.1 More Complex Graphical Approaches
When multiple endpoints as well as multiple populations are considered in a
trial, we suggest applying CCS to the hypotheses with the same endpoint. For
instance, Figure 4 shows a hypothetical case using a graphical multiplicity ap-
proach similar to Example 2 in [3] that includes only part of the correlation ma-
trix known. There are two endpoints (OS and progression-free survival (PFS))
and two populations. CCS needs to be conducted twice, one time for OS and
another time for PFS. For OS, there is a total alpha of 2% available. Split-
ting this equally, we can test for OS differences initially using the CCS methods
shown above. The transfer of nominal alpha once a hypothesis has been rejected
is not impacted by CCS; e.g., if H2 were rejected, then H1 may be tested at
level alpha=2%. Similarly, if H1 and H2 both are rejected, there is total 2%
alpha level that can be transferred to H3 and H4 equally, e.g. 1% alpha level
to H3, and 1% alpha level to H4. Since there are only 2 populations, there are
still no consonance issues. The gain of nominal α-level from CCS (e.g. CCS-α
of 1.1% in H1 and H2 or CCS-α of 0.3% in H3 and H4) is only available to the
hypothesis testing within the endpoint itself.
6.2 Multi-Arm Multi-Stage Multi-Population (MAMSMP)
Trials
We focus on 2-arm trials in previous sections, but the weighted parametric closed
testing procedure has been extended to multiple-arm designs [7, 26, 10]. Based
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Figure 4: Graphical Approach with CCS Adjusted α-levels.
on the results here, multiplicity for multi-arm, multi-stage, multi-population
(MAMSMP) designs can fully account for correlations when designing and ana-
lyzing the trial. For example, consider a 3-arm, 2-population trial comparing 2
dose arms (e.g., high-dose and low-dose) against a control arm when one interim
analysis is planned. Let ZHik be the test statistics when comparing high-dose
with control, and ZLik be the test statistics for comparing low-dose with con-
trol. The CCS correlation matrix is a 8× 8 matrix for the 8 test statistics (i.e.,
(ZH11, ZH12, ZH21, ZH22, ZL11, ZL12, ZL21, ZL22). The covariance of any two of
above test statistics is as explained in Section 3.1. Particularly, the covariance
of (ZHik, ZLi′k′) is the correlation from the control observations that are in-
cluded in both high-dose and low-dose test statistics. Once the CCS matrix is
known, calculations described in the Section 3 for group sequential monitoring
boundaries, power, and sample size can be applied to MAMSMP design.
7 Discussion
In this paper, we have introduced the complete correlation structure (CCS)
to manage both temporal and subpopulation correlations among test statistics
in group sequential design. To our knowledge, this is the first paper that has
accounted for these two aspects simultaneously in a clinical trial design for
nested subgroups. The approach has been used previously for multi-arm multi-
stage trials [7, 26, 10]. By synthesizing concepts from the literature, we have
built upon the CCS to compute group sequential boundaries, population power,
and sample size with weighted parametric closed testing procedure using the
graphical approach for multiplicity control [16]. The advantages of using the
CCS include more relaxed efficacy boundaries (i.e., greater nominal alpha level),
higher population power, or smaller required sample size for a given FWER. The
method can be applied to multiple types of outcomes (e.g. normal, binary, and
survival type) since it is based on standardized test statistics with the same
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asymptotic properties.
We have examined the influence of biomarker prevalence on nominal alpha
level, population power, and sample size (Figure 1 Figure 3). The impact
of the proportion in the subgroup was more influential than group sequential
adjustment over time in interim analysis, probably due to the small amount of
interim α-spending for the temporal analyses. In group sequential design with
the Bonferroni-style of FWER control, we account for the correlation among
test statistics at different stages, but the correlation between populations is not
incorporated.
When the nominal alpha level is elevated by CCS in group sequential design,
the boundary values for hypothesis testing are lowered. In the example at
Section 5, the nominal alpha level increases by 0.28% in each population. This
improvement increases the chance for a positive efficacy finding. Corresponding
HR approximations at bounds are also less stringent when FWER is controlled
at the same 2.5% significance level. While these differences may appear minor,
narrow misses for statistical significance can be extremely costly in terms of lost
opportunity for regulatory approval. Also, the amount the bounds are relaxed
are not so different than what can be obtained with group sequential testing
accounting for temperal correlations (standard practice) vs. using a Bonferroni
adjustment for group sequential testing. The financial savings of $3.3 million is
important and the cost saving would increase if biomarker prevalence is higher
than our assumption at 60%. In terms of population power, we have showed CCS
in group sequential design had greater power to detect treatment effect while
sample size and effect size were fixed, again confirming the cost-effectiveness of
this approach.
We have discussed the extension of CCS in Section 6 that CCS is suitable
to multiple-arm design and more complex graphical approach with some con-
straints. These options make application of CCS feasible for a variety of clinical
trial designs, a subject of ongoing research.
Unfortunately, off-the-shelf software does not provide tools to derive designs
or testing for trials incorporating CCS for nested subgroups. However, the
calculations are not terribly complex using readily available tools in R such
as a combination of the gsDesign package [1] for group sequential design, the
gMCP package [22] for graphical hypothesis testing and the mvtnorm package
[6] for multivariate normal probability calculations.
8 Conclusion
The complete correlation structure (CCS) approach simultaneously incorporates
correlations between populations and interim timing into group sequential de-
sign. It has an extensive application to the methods that are widely used in
current clinical trials, and it is applicable to designs with multiple arms, mul-
tiple stages, and multiple populations. It can also can be integrated with the
graphical testing approach with the qualification that for more than 2 popula-
tions a full closed testing evaluation may be required. The gains in efficiency
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of applying the CCS in group sequential design as compared to conventional
group sequential design includes more relaxed efficacy boundaries (i.e., larger
nominal α-level at each test), resulting in greater power or reduced sample size
that are small, but meaningful; in fact, the gains from considering population
correlations can be greater than those achieved by incorporating broadly-used
temporal correlations.
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